GSK plc (GSK.L) Wednesday said its therapeutic herpes simplex virus (HSV) vaccine candidate GSK3943104 failed to meet the primary goal in Phase I/II study.
A primary objective data analysis from the phase II part of the Phase I/II TH HSV REC-003 study showed that the vaccine candidate did not meet the study's primary efficacy point. Therefore, the company plans not to take GSK3943104 to Phase III studies.
The TH HSV REC-003 study will continue for routine safety monitoring and to generate follow-up data that could offer valuable insights into recurrent genital herpes, GSK said in a statement.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.